Please login to the form below

Not currently logged in
Email:
Password:

ABPI backs value based pricing

UK industry organisation voices its support for government proposals on valuing medicines as consultation period comes to a close

The Association of the British Pharmaceutical Industry (ABPI) has given its backing to UK government proposals to move to a system of value based pricing (VBP) for medicines.

Unveiling its response to the government's consultation on VBP at a press conference in London yesterday (March 14), the ABPI said that it strongly supported the principle for value to reflect the level of innovation and be based on wider issues, especially those that mattered most to patients.

It added that it wanted the role of research and development to be fully reflected in the future system.

The ABPI's response included three key points: that VBP must be integrated with the current pricing scheme for existing products; that the NHS needed to play a key role and ensure that value-proven medicines were used by clinicians; and that the NHS Commissioning Board should be involved in the development of proposals for VBP to secure medicines access and uptake.

Richard Barker, ABPI director general, said: "Value based pricing needs to be approached with extreme care. It should not be designed in isolation. The UK plays a leading role in this area and the rest of the world will be looking at us to see if we understand innovation and whether our system works."

Patient group National Voices also welcomed the government's objective, but said that there was still a long way to go in the policy development process. This became clearer as the event went on, as the ABPI revealed that the most important details, such as who would be involved in future price negotiations and the pricing structure itself, had yet to be discussed.

The government launched the consultation on December 16; it closes on March 17.

15th March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics